Sienna Biopharmaceuticals Inc (NASDAQ:SNNA)’s share price reached a new 52-week low during trading on Monday . The stock traded as low as $1.93 and last traded at $1.99, with a volume of 2336 shares changing hands. The stock had previously closed at $2.16.

Several equities analysts recently commented on SNNA shares. Zacks Investment Research downgraded Sienna Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. ValuEngine downgraded Sienna Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th.

The company has a debt-to-equity ratio of 1.13, a current ratio of 2.07 and a quick ratio of 2.07. The company has a market cap of $65.62 million, a P/E ratio of -0.57 and a beta of 3.64.

Sienna Biopharmaceuticals (NASDAQ:SNNA) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.10). Analysts expect that Sienna Biopharmaceuticals Inc will post -0.99 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of SNNA. Bank of New York Mellon Corp lifted its position in shares of Sienna Biopharmaceuticals by 18.1% during the third quarter. Bank of New York Mellon Corp now owns 43,627 shares of the company’s stock worth $647,000 after acquiring an additional 6,682 shares in the last quarter. BlackRock Inc. lifted its position in shares of Sienna Biopharmaceuticals by 3.0% during the third quarter. BlackRock Inc. now owns 1,040,257 shares of the company’s stock worth $15,417,000 after acquiring an additional 29,919 shares in the last quarter. FMR LLC lifted its position in shares of Sienna Biopharmaceuticals by 0.3% during the third quarter. FMR LLC now owns 3,119,969 shares of the company’s stock worth $46,238,000 after acquiring an additional 10,109 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Sienna Biopharmaceuticals during the third quarter worth $200,000. Finally, Jane Street Group LLC purchased a new stake in shares of Sienna Biopharmaceuticals during the third quarter worth $182,000. Hedge funds and other institutional investors own 30.59% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Sienna Biopharmaceuticals (SNNA) Sets New 52-Week Low at $1.93” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2019/04/15/sienna-biopharmaceuticals-snna-sets-new-52-week-low-at-1-93.html.

About Sienna Biopharmaceuticals (NASDAQ:SNNA)

Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.

Further Reading: Treasury Bonds

Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.